Greetings! Welcome to the first edition of the PBM-MAP Ez Minutes!
The newsletter is intended to keep you well informed regarding the items discussed during the PBM-MAP meetings. The newsletter will contain the minutes that one can literally read in minutes as well as other "hot" items! So enjoy and read on and be sure to check the Web site at www.vapbm.org or vaww.pbm.med.va.gov for other breaking news.

Recent National PBM Reviews Postings on Web site

Criteria for Use
http://www.vapbm.org/PBM/criteria.htm
Adefovir
Clopidogrel
Leukotriene Inhibitor use in allergic rhinitis
Ramipril

Criteria for Nonformulary Use
http://www.vapbm.org/PBM/criteria.htm
Buprenorphine SL Tablets for Opioid Dependence
Ezetimibe
Implantable Leuprolide Delivery System Viadur
Ziprasidone IM

Drug Class Reviews
http://www.vapbm.org/PBM/reviews.htm
Luteinizing Hormone Releasing Hormone LHRH Agonist in Prostate Cancer

Drug Monographs
http://www.vapbm.org/PBM/drugmonograph.htm
Adefovir Dipivoxil
Aripiprazole –revised 2/03
Atomoxetine
Buprenorphine and Buprenorphine/Naloxone
Escitalopram
Ezetimibe
Montelukast in seasonal allergic rhinitis Oxaliplatin
Ziprasidone

New Molecular Entities Reviews
● Adefovir-Not added to VA National Formulary (VANF), VISNs may add with restrictions.
● Aripiprazole-Not added to VANF or VISN Formularies
● Tegaserod-Not added to VANF or VISN Formularies
● Atomoxetine-Not added to VANF or VISN Formularies
● Ezetimibe-Not added to VANF or VISN Formularies-local availability by non-formulary waiver and/or by criteria

New Items
Buprenorphine SL Tablets for Opioid Dependence-Not added to VANF, VISNs may add with restrictions.

PBM Members
TORRISI, Virginia
Deputy Chief Consultant, PBM
VALENTINO, Michael
Assoc. Chief Consultant, PBM
CANZOLINO, Joseph
Asst Chief Consultant, PBM
BURK, Muriel
CHANDLER, Christine
CUNNINGHAM, Fran
FURMAGA, Elaine
GERACI, Mark
GOLTERMAN, Lori
GOODMAN, Francine
KELLEY, Cathy
KHACHIKIAN, Debbie
TORTORICE, Kathy

Volume 1, Issue 1
May 2003

Inside this issue:
Greetings
National PBM Reviews
New Molecular Entities
National Tamsulosin Drug Use Evaluation
Members of the PBM-MAP Video Satellite Broadcast Programs
ALLHAT Study
JNC 7 New Guidelines
Nifedipine Monitoring Utilization/Patient Safety

Coming Soon! CE Satellite Programs!

1. Hypertension in VA (Program One) “Results of ALLHAT: The Largest HTN Trial Ever” Live- May 29th, 12:00-1pm ET;
Rebroadcast on June 5th 11:00 am ET, June 11th 5:00pm ET, and July 1st at 3pm ET.
For more information: http://vaww.sites.lrn.va.gov/vacatalog/cu_detail.asp?id=16412

Results of the National Tamsulosin Drug Use Evaluation

- 6 VA sites (n=332) were included
- 66% of patients prescribed tamsulosin had appropriate indications according to the national criteria; 4% had potentially appropriate indications
- 30% of patients were prescribed tamsulosin for reasons not consistent with the criteria
- On follow-up for patients prescribed tamsulosin
  Over 25% of patients were not assessed for efficacy
  ~15% of patients remained on tamsulosin when it was documented to be ineffective.
  ~ 34% of patients continued on tamsulosin were not evaluated for side effects of the medication.

### COST COMPARISON

<table>
<thead>
<tr>
<th>ALPHA-BLOCKER</th>
<th>USUAL DOSE RANGE for BPH</th>
<th>COST/MONTH&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VA National Formulary</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxazosin (1, 2, 4, 8mg tabs)</td>
<td>1-8mg qd&lt;sup&gt;a&lt;/sup&gt;</td>
<td>$1.53-$2.81</td>
</tr>
<tr>
<td>Prazosin (1, 2, 5mg caps)</td>
<td>1-5mg bid&lt;sup&gt;a&lt;/sup&gt; (2mg bid used in clinical trials)</td>
<td>$1.30-$2.67</td>
</tr>
<tr>
<td>Terazosin (1, 2, 5, 10mg tabs or caps)</td>
<td>1-10mg qd&lt;sup&gt;a&lt;/sup&gt;</td>
<td>$1.49-$2.39</td>
</tr>
<tr>
<td><strong>Non-Formulary</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tamsulosin (0.4mg capsules)</td>
<td>0.4mg qd&lt;sup&gt;c&lt;/sup&gt;</td>
<td>$22.48</td>
</tr>
</tbody>
</table>

<sup>a</sup> Initial dose of 1mg should be given at bedtime. The dose may be increased every 2 to 4 weeks based on response

<sup>b</sup> Based on current Federal Supply Schedule or VA Contract Price

<sup>c</sup> Increased dose not found to be consistently more effective, however manufacturer information states dose may be increased to 0.8mg qd. If dose is increased, patient should be reassessed and dose decreased or discontinued if inadequate response since higher doses have been associated with increased side effects

### Summary of PBM-MAP Criteria for Non-Formulary Use of Tamsulosin in VA Patients with BPH

Consider tamsulosin if patient has or develops the following while on a VANF alpha-blocker

- Significant symptomatic hypotension
- Significant orthostatic or postural symptoms; or at baseline
- Syncope or near syncope symptoms
- Significant adverse event (consider ↓ dose or trial of alternate alpha-blocker)

Consider tamsulosin in patients with BPH and HTN in the following situations

- Doxazosin/prazosin/terazosin monotherapy for HTN
  - First consider adding another antihypertensive agent; if symptomatic ↓ BP despite lowest dose alpha-blocker, consider change to tamsulosin

**Normotensive on antihypertensive regimen**

- Adjust antihypertensive treatment upon initiation of a VANF alpha-blocker; if symptomatic ↓ BP despite adjustment of antihypertensive therapy, consider replacing alpha-blocker with tamsulosin

Refer to complete criteria for use at [http://www.vapbm.org/criteria/tamsulosincriteria.pdf](http://www.vapbm.org/criteria/tamsulosincriteria.pdf)
RECOMMENDATIONS BASED ON TAMСULOSIN DUE

- Emphasize selected circumstances where tamsulosin may be considered (refer to summary of criteria above)
- Recommend dose adjustment of the formulary alpha-blockers, when appropriate, to minimize adverse drug events before prescribing tamsulosin
- Adjust antihypertensive medications in patients with BPH and HTN prior to prescribing tamsulosin
- Emphasize appropriate follow-up on tamsulosin (especially patients on 0.8mg) to assess for efficacy and side effects (Note: two to four weeks may be necessary before patient response can be assessed) Implement national criteria in a timely fashion
- Tailor the method of implementation to the facility
- Consider provider education (appears more successful than other methods of implementation)

ALLHAT STUDY

The objective of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was to determine whether coronary heart disease and other cardiovascular events differ between diuretic based and alternative antihypertensive pharmacological treatment with an angiotensin-converting enzyme inhibitor, a calcium channel blocker, or an alpha-blocker. The ALLHAT hypertension study results indicate that less costly, traditional diuretics are more effective than newer medicines in preventing some forms of heart disease. Because of their superiority in preventing one or more major forms of CVD and their lower cost, thiazide-type diuretics should be the drugs of choice for initial treatment of HTN in most patients requiring drug therapy. For additional information click on http://www.nhlbi.nih.gov/health/allhat/index.htm.

What do the national HTN Guidelines suggest?

Monitoring Utilization of Short-Acting Nifedipine

Background: Short-acting nifedipine has been associated with a significant, dose-related increase in mortality in patients with myocardial infarction, unstable angina, or who are undergoing angiography. A review of the literature found short-acting nifedipine to precipitate ischemic events when given by the sublingual route for hypertensive urgencies/emergencies. In addition, short-acting nifedipine is not FDA approved for the treatment of hypertension. The NHLBI recommended short-acting nifedipine be used with great caution in patients with hypertension, angina, or myocardial infarction.
Action: Short-acting nifedipine is restricted to the following clinical situations:

1. Spinal cord injury patients to treat hypertension due to autonomic dysreflexia
2. Patients with hypertensive urgency requiring blood pressure reduction prior to anesthesia induction in the operating room
3. Patients with vasospastic angina in the cath lab

Follow-up:

A utilization report by VAMC was disseminated 8/2000 with interventions recommended in those VISNs where utilization was substantially higher compared to other VISNs. Follow-up report 3/2001 showed decreased utilization through education and ongoing intervention, especially in those VISNs where initial use was high (See attached table) It was recommended to continue interventions in outlying VISNs and periodically monitor utilization.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>VISN 1</td>
<td>64,236</td>
<td>55,246</td>
<td>53,650</td>
<td>60,134</td>
</tr>
<tr>
<td>VISN 2</td>
<td>17,254</td>
<td>9,818</td>
<td>3,826</td>
<td>4,096</td>
</tr>
<tr>
<td>VISN 3</td>
<td>69,334</td>
<td>49,935</td>
<td>35,295</td>
<td>31,730</td>
</tr>
<tr>
<td>VISN 4</td>
<td>79,334</td>
<td>54,595</td>
<td>30,462</td>
<td>29,592</td>
</tr>
<tr>
<td>VISN 5</td>
<td>21,573</td>
<td>19,370</td>
<td>18,963</td>
<td>13,015</td>
</tr>
<tr>
<td>VISN 6</td>
<td>66,253</td>
<td>63,516</td>
<td>52,792</td>
<td>58,829</td>
</tr>
<tr>
<td>VISN 7</td>
<td>88,733</td>
<td>55,462</td>
<td>35,463</td>
<td>31,561</td>
</tr>
<tr>
<td>VISN 8</td>
<td>535,415</td>
<td>344,415</td>
<td>91,325</td>
<td>25,036</td>
</tr>
<tr>
<td>VISN 9</td>
<td>82,420</td>
<td>40,621</td>
<td>25,273</td>
<td>27,046</td>
</tr>
<tr>
<td>VISN 10</td>
<td>132,411</td>
<td>70,273</td>
<td>45,005</td>
<td>17,717</td>
</tr>
<tr>
<td>VISN 11</td>
<td>72,421</td>
<td>51,886</td>
<td>45,466</td>
<td>43,428</td>
</tr>
<tr>
<td>VISN 12</td>
<td>61,202</td>
<td>44,896</td>
<td>21,734</td>
<td>18,031</td>
</tr>
<tr>
<td>VISN 13</td>
<td>24,890</td>
<td>13,790</td>
<td>14,090</td>
<td>14,996</td>
</tr>
<tr>
<td>VISN 14</td>
<td>338,667</td>
<td>200,032</td>
<td>116,964</td>
<td>93,879</td>
</tr>
<tr>
<td>VISN 15</td>
<td>68,767</td>
<td>53,571</td>
<td>40,654</td>
<td>37,590</td>
</tr>
<tr>
<td>VISN 16</td>
<td>31,623</td>
<td>27,528</td>
<td>24,399</td>
<td>20,468</td>
</tr>
<tr>
<td>VISN 17</td>
<td>59,813</td>
<td>42,474</td>
<td>30,633</td>
<td>17,767</td>
</tr>
<tr>
<td>VISN 18</td>
<td>23,923</td>
<td>18,422</td>
<td>15,462</td>
<td>9,870</td>
</tr>
<tr>
<td>VISN 19</td>
<td>21,350</td>
<td>15,298</td>
<td>8,652</td>
<td>5,368</td>
</tr>
<tr>
<td>VISN 20</td>
<td>27,332</td>
<td>13,126</td>
<td>10,681</td>
<td>6,495</td>
</tr>
<tr>
<td>VISN 21</td>
<td>182,743</td>
<td>125,417</td>
<td>82,511</td>
<td>79,853</td>
</tr>
</tbody>
</table>